SULT2A1

Sulfotransferase 2A1

214 patent compounds predicted against SULT2A1, 193 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9904844	1.00	1/20
SCHEMBL9904845	1.00	1/20
SCHEMBL11919898	1.00	1/20
SCHEMBL29372843	1.00	1/20
SCHEMBL35212190	1.00	1/20
SCHEMBL9905154	0.86	1/20
SCHEMBL9905155	0.86	1/20
SCHEMBL11919903	0.86	1/20
SCHEMBL23772382	0.86	1/20
SCHEMBL16010756	0.86	1/20
SCHEMBL9926244	0.85	1/20
SCHEMBL15449894	0.84	1/20
SCHEMBL11919900	0.83	1/20
SCHEMBL9926210	0.81	1/20
SCHEMBL11919901	0.80	1/20
SCHEMBL13046998	0.80	1/20
SCHEMBL15449865	0.79	1/20
SCHEMBL11919979	0.77	1/20
SCHEMBL15449805	0.75	1/20
SCHEMBL11919910	0.75	1/20

Germline variants in SULT2A1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full SULT2A1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to SULT2A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Comparison of Two Different Doses of Paracetamol for Post-Operative Pain Relief	PHASE4	COMPLETED
Pharmacogenetics of Nicotine Addiction Treatment	PHASE3	COMPLETED
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer	PHASE2	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Variability of Sulfotransferase 1A1 Activity in Humans: an Approach to Improve Predictive Drug Response - Part I: Analysis of Intraindividual Variation in Healthy Adults	PHASE1	COMPLETED
Variability of Sulfotransferase Activity in Humans: an Approach to Improve Predictive Drug Response Part II: Analysis of Interindividual Variation in Hypertensive Patients	PHASE1	COMPLETED
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine	PHASE1	COMPLETED
Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects	PHASE1	COMPLETED
Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study	PHASE1	COMPLETED
Bioavailability of Paracetamol, Amoxicillin and Talinolol Before, Immediately and One Year After Gastric Bypass Operation	PHASE1	COMPLETED
PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers	PHASE1	COMPLETED
Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects	PHASE1	COMPLETED
Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet	EARLY_PHASE1	COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac	EARLY_PHASE1	RECRUITING
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline	nan	COMPLETED
APAP Hepatotoxicity After Therapeutic Doses	nan	UNKNOWN
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype	nan	UNKNOWN
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6	nan	COMPLETED
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant	nan	RECRUITING
Aromatase Inhibitor Clinical Trial	nan	UNKNOWN
Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva	nan	COMPLETED
Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer	nan	COMPLETED
Individualized Antiretroviral Therapy	nan	COMPLETED
Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer	nan	COMPLETED
Effects of Genotype on CYP2C9 Drug Interactions	nan	COMPLETED
Pharmacogenetic Determinants Of Treatment Response In Children	nan	RECRUITING
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SULT2A1 binder may also engage these)

Protein	Name	Similarity
P52841	—	1.000	P52841 →
P52842	—	1.000	P52842 →
B2RVI8	—	0.999	B2RVI8 →
P50236	—	0.997	P50236 →
P15709	—	0.995	P15709 →
P22789	—	0.994	P22789 →
P52843	—	0.993	P52843 →
P50234	—	0.992	P50234 →
P50235	—	0.991	P50235 →
Q29476	—	0.989	Q29476 →
P49887	—	0.989	P49887 →
P19217	—	0.989	P19217 →
Q9QWG7	—	0.989	Q9QWG7 →
Q6WG18	—	0.988	Q6WG18 →
Q8BGL3	—	0.988	Q8BGL3 →
O43704	—	0.988	O43704 →
P52840	—	0.988	P52840 →
G3V9R3	—	0.988	G3V9R3 →
Q3UZZ6	—	0.988	Q3UZZ6 →
P0DMM9	—	0.987	P0DMM9 →
P0CC03	—	0.987	P0CC03 →
P0DMN0	—	0.986	P0DMN0 →
Q9WUW9	—	0.986	Q9WUW9 →
SULT1A1	Sulfotransferase 1A1	0.986	landscape →
A0A2K5X3B6	—	0.986	A0A2K5X3B6 →
Q6IMI4	—	0.986	Q6IMI4 →
O00338	—	0.986	O00338 →
Q6PH37	—	0.985	Q6PH37 →
P50227	—	0.985	P50227 →
O46503	—	0.985	O46503 →